67 related articles for article (PubMed ID: 7654043)
1. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients.
Scorilas A; Yotis J; Stravolemos K; Gouriotis D; Keramopoulos A; Ampela K; Talieri M; Trangas T
Anticancer Res; 1995; 15(4):1543-7. PubMed ID: 7654043
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients.
Scorilas A; Yotis J; Gouriotis D; Keramopoulos A; Ampela K; Trangas T; Talieri M
Anticancer Res; 1993; 13(5C):1895-900. PubMed ID: 7903524
[TBL] [Abstract][Full Text] [Related]
3. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
[TBL] [Abstract][Full Text] [Related]
4. [Amplification of c-myc and c-erbbeta-2(HER-2/neu) in breast cancer without axillary lymph node metastasis: correlation with other prognostic parameters].
Lizard-Nacol S; Arnould L; Riedinger JM; Arnal M; Collin F; Guerrin J
Bull Cancer; 1994 Sep; 81(9):780-4. PubMed ID: 7703567
[TBL] [Abstract][Full Text] [Related]
5. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
[TBL] [Abstract][Full Text] [Related]
9. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
Erdogan S; Ergin M; Tuncer I
Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
[TBL] [Abstract][Full Text] [Related]
10. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction.
Naidu R; Wahab NA; Yadav M; Kutty MK
Int J Mol Med; 2002 Feb; 9(2):189-96. PubMed ID: 11786932
[TBL] [Abstract][Full Text] [Related]
11. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors?
Underwood M; Bartlett J; Reeves J; Gardiner DS; Scott R; Cooke T
Cancer Res; 1995 Jun; 55(11):2422-30. PubMed ID: 7757996
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
[TBL] [Abstract][Full Text] [Related]
13. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing.
Schmidt M; Lewark B; Kohlschmidt N; Glawatz C; Steiner E; Tanner B; Pilch H; Weikel W; Kölbl H; Lehr HA
Breast Cancer Res; 2005; 7(2):R256-66. PubMed ID: 15743506
[TBL] [Abstract][Full Text] [Related]
14. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients.
Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG
Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867
[TBL] [Abstract][Full Text] [Related]
15. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
Berger MS; Locher GW; Saurer S; Gullick WJ; Waterfield MD; Groner B; Hynes NE
Cancer Res; 1988 Mar; 48(5):1238-43. PubMed ID: 2893663
[TBL] [Abstract][Full Text] [Related]
16. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
[TBL] [Abstract][Full Text] [Related]
17. Combined overexpression of c-erbB-2 protein and epidermal growth factor receptor (EGF-R) could be predictive of early and long-term outcome in human breast cancer: a pilot study.
Delarue JC; Terrier P; Terrier-Lacombe MJ; Mouriesse H; Gotteland M; May-Levin F
Bull Cancer; 1994 Dec; 81(12):1067-77. PubMed ID: 7742595
[TBL] [Abstract][Full Text] [Related]
18. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
[TBL] [Abstract][Full Text] [Related]
19. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.
Scorilas A; Yotis J; Pateras C; Trangas T; Talieri M
Clin Cancer Res; 1999 Apr; 5(4):815-21. PubMed ID: 10213217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]